×
Crossing the borders of innovation
Basing clinical trials on sound mechanistic and scientific rationale.
Combating Pan-Cancer with Precision
Saving Lives of Patients Who Exhausted Treatment Options and Improving Clinical Benefits
Cancer Patients are fighting for their lives...
we will fight with them
Imagining a world without cancer.
previous arrow
next arrow
Slider

Apollomics is an innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies.

Apollomics-pipeline_v2

Pipeline

Our-Approach

Science

Apollomics_PR

Events

Our Vision

To become a global leader in the development of novel medicines for cancer patients.

Learn More

Recent News

May 21, 2020

Apollomics, Inc. Announces Initiation of SPARTA Phase 2 Clinical Trial for c-MET Inhibitor APL-101

January 6, 2020

GlycoMimetics and Apollomics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Uproleselan and GMI-1687 in Greater China
More News